A5032114353- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- CAR-T cell therapy research
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- HIV/AIDS drug development and treatment
- vaccines and immunoinformatics approaches
- Head and Neck Surgical Oncology
- Histone Deacetylase Inhibitors Research
- Cancer Genomics and Diagnostics
- Protist diversity and phylogeny
- Cancer, Hypoxia, and Metabolism
- Neutropenia and Cancer Infections
- Nanoparticle-Based Drug Delivery
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
University of St. Gallen
2001-2025
Kantonsspital St. Gallen
2013-2023
Kantonsspital Baden
2015
Swiss Group For Clinical Cancer Research
2004-2010
Heisei International University
2009
Sigma-Tau (Switzerland)
2009
University of Modena and Reggio Emilia
2007
Red Cross Hospital
2006
The Netherlands Cancer Institute
2006
Essen University Hospital
2005
In this study, two doses of temsirolimus (CCI-779), a novel inhibitor the mammalian target rapamycin, were evaluated for efficacy, safety, and pharmacokinetics in patients with locally advanced or metastatic breast cancer who had been heavily pretreated.Patients (n = 109) randomly assigned to receive 75 250 mg weekly as 30-minute intravenous infusion. Patients tumor response, time progression, adverse events, temsirolimus.Temsirolimus produced an objective response rate 9.2% (10 partial...
CB-103 selectively inhibits the CSL-NICD (Notch intracellular domain) interaction leading to transcriptional downregulation of oncogenic Notch pathway activation. This dose-escalation/expansion study aimed determine safety, pharmacokinetics, and preliminary antitumor activity.
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved treatment1. Yet, response rates still limited, tumour progression commonly occurs2. Soluble cell-bound factors in the microenvironment negatively affect immunity. Recently, growth differentiation factor 15 (GDF-15), a cytokine that is abundantly produced by many types, was shown to interfere antitumour response. In preclinical models,...
Downregulation of the unfolded protein response mediates proteasome inhibitor resistance in multiple myeloma. The Human Immunodeficieny Virus protease nelfinavir activates vitro. We determined dose-limiting toxicity and recommended dose for phase II combination with bortezomib. Twelve patients advanced hematologic malignancies were treated (2500–5000 mg/day p.o., days 1–14, 3+3 escalation) bortezomib (1.3 mg/m2, 1, 4, 8, 11; 21-day cycles). A run monotherapy allowed...
Background TLD-1 is a novel liposomal doxorubicin that compared favorably to conventional formulations in preclinical models. This phase I first-in-human study aimed define the maximum tolerated dose (MTD), recommended 2 (RP2D), safety and preliminary activity of patients with advanced solid tumors. Patients methods We recruited tumors who failed standard therapy received up 3 prior lines palliative systemic chemotherapy. was administered intravenously every weeks 9 cycles (6 for...
Background ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding IL-2 the α subunit its receptor but has selective affinity for βγ subunits. Thus, preferentially stimulates CD8 + effector T cells and natural killer which are associated with tumor killing, while minimizing activation immunosuppressive regulatory cells. Methods ANV419-001 open-label, multicenter, phase 1 study evaluate...
Tinostamustine is a first-in-class alkylating deacetylase inhibitor that facilitates access to cancer cell DNA, resulting in its damage and counteracting DNA repair systems. We hypothesize the addition of tinostamustine immune checkpoint inhibitors (ICIs) improves melanoma treatment. This open-label, nonrandomized phase IB study characterized dose-limiting toxicity (DLT) recommended dose (RD) 2-weekly intravenous at escalating doses 15 30 mg/m 2 when administered with nivolumab 3 mg/kg added...
Abstract Therapeutic blockade of PD-1:PD-L1/L2 interactions is effective in many cancers, particularly those with pre-existing inflammation and T cell infiltration. We identified a correlation between high interleukin 4 induced 1 (IL4I1) gene expression within the tumor micorenvironment (TME) tumors response to PD-1 inhibitor pembrolizumab (pembro). IL4I1 protein secreted by myeloid cells into extracellular TME where it generates hydrogen peroxide upon deamination amino acid substrates,...
Synergistic/additive cytotoxicity in tumor models and widespread applicability of fluoropyrimidines solid tumors prompted the study combination mammalian target rapamycin (mTOR) inhibitor, non-prodrug analog ridaforolimus, with capecitabine.Thirty-two adult patients were treated. Intravenous ridaforolimus was given once weekly for 3 weeks capecitabine from days 1 to 14 every 4 weeks. Ridaforolimus at 25, 37.5, 50, or 75 mg 1,650 mg/m(2) 1,800 divided into two daily doses. Pharmacokinetics...
3020 Background: CB-103 selectively inhibits the CSL-NICD interaction leading to down-regulation of mediated oncogenic pathway activation downstream NOTCH receptor/ligand signaling, and has shown potent anti-cancer activity as single agent in combination with targeted/chemotherapies preclinical models. The aim this dose escalation/expansion phase 1/2a study is assess safety, maximum tolerated (MTD) recommended 2 (RP2D), preliminary activity, pharmacokinetics pharmacodynamics CB-103. Methods:...